Prostate Cancer
Pluvicto Improves Survival in Earlier Prostate Cancer, But Faces Regulatory Hurdles (ESMO 2023)
ESMO 2023: LBA13 Novartis is eagerly advancing its radiotherapy drug, Pluvicto, with aspirations of its potential in earlier prostate cancer ...
Ambrx’s ARX517 Shows Promising Efficacy and Safety in Advanced Prostate Cancer (ESMO 2023)
ESMO 2023: 1804P As of the data cutoff date in September 2023, the results from the study show that increasing ...
Resilient Triumph: Roche and Exelixis’ Tecentriq-Cabometyx Combination Shows Promise in Advanced Prostate Cancer After Past Challenges
After facing setbacks in clinical trials, the combination of Roche’s Tecentriq and Exelixis’ Cabometyx has achieved a breakthrough in treating ...
Johnson & Johnson Breaks Into Prostate Cancer Market with Akeega
After the FDA’s green light for AstraZeneca/Merck and Pfizer’s PARP inhibitors, Johnson & Johnson (J&J) has now secured its own ...
A2R, a prostate cancer medication, is discontinued by Arcus and Gilead
Arcus and Gilead Sciences have opted to discontinue the development of their A2 receptor antagonist, etrumadenant, for castration-resistant prostate cancer ...
Prostate Cancer Treatment: What Every Man Should Know About and How to Treat It
Everything You Need to Know About Prostate Cancer Treatment and Prevention A lot of men are affected by prostate cancer, ...
Talazoparib Plus Enzalutamide for HRR Gene-Altered mCRPC Receives FDA Approval
Source – FDA On June 20, 2023, the combination of talazoparib (Talzenna) and enzalutamide (Xtandi) has been approved by the ...
Pfizer Joins Prostate Cancer PARP Showdown: A Three-Way Battle for Breakthrough Treatment
Pfizer expects that the FDA’s approval of Talzenna, a PARP inhibitor, for castration-resistant prostate cancer (CRPC) would enable it to ...
Obstacles Faced by Oncologists in Accessing PSMA-Targeted Therapy for Prostate Cancer treatment
Therapy for Prostate Cancer treatment: After progressing on docetaxel and an androgen receptor (AR)-targeted therapy, patients with metastatic castration-resistant Prostate ...
